Genetic Variation in TRAF3IP2 (rs13190932)
Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathog
| Condition(s) | Psoriasis, Psoriatic Arthritis |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement. |
| Who can participate | Inclusion Criteria: * Patients aged 18 -70years . * the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist. * Willingness to participate: Signed informed consent. * Initiating methotrexate (MTX) therapy: For prospective cohort. * Availability for follow-up: Patients must be willing and able to attend scheduled visit. Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disor |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | South Valley University |
| Locations | Qina, Egypt |
| Start date | 2025-06-01 |
| NCT ID | NCT07086924 |
| Official listing | https://clinicaltrials.gov/study/NCT07086924 |